However, several new agents designed to overcome this problem are currently in clinical use or in development, including T-cell checkpoint blockade approaches (anti-CTLA4, anti-PD1/PD-L1), depletion/conversion of tumor-associated myeloid cells (CSF1 inhibitors), suppressive enzyme inhibition (indolamine deoxygenase (IDO) inhibitors), or oncogene-targeted agents (BRAF-V600E inhibitors).23 The gene discussed is CD274; the disease is neoplasm.